Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis Portfolio News / Karina Tin November 28, 2023 Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis Read More »
RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy Portfolio News / Karina Tin November 27, 2023 RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy Read More »
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes Portfolio News / Karina Tin November 15, 2023 Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes Read More »
RAPT Therapeutics Reports Third Quarter 2023 Financial Results Portfolio News / Karina Tin November 13, 2023 RAPT Therapeutics Reports Third Quarter 2023 Financial Results Read More »
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Portfolio News / Karina Tin November 13, 2023 NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Read More »
Kallyope and Sosei Heptares Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Portfolio News / Karina Tin November 10, 2023 Kallyope and Sosei Heptares Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Read More »
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Portfolio News / Karina Tin November 8, 2023 Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Read More »
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Portfolio News / Karina Tin November 6, 2023 ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Read More »
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC Portfolio News / Karina Tin November 3, 2023 RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC Read More »
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Portfolio News / Karina Tin November 2, 2023 A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More »
